{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:27:42Z","timestamp":1771327662533,"version":"3.50.1"},"reference-count":333,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Program for Pearl River New Stars of Science and Technology","award":["201906010010"],"award-info":[{"award-number":["201906010010"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873080"],"award-info":[{"award-number":["81873080"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Major Scientific and Technological Projects of Guangdong Province","award":["2019B020202002"],"award-info":[{"award-number":["2019B020202002"]}]},{"name":"Chinese Academy of Traditional Chinese Medicine","award":["ZZ13-035-02"],"award-info":[{"award-number":["ZZ13-035-02"]}]},{"name":"Chinese Academy of Traditional Chinese Medicine","award":["2019XZZX-LG04"],"award-info":[{"award-number":["2019XZZX-LG04"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.pharmthera.2020.107671","type":"journal-article","created":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T03:11:33Z","timestamp":1599534693000},"page":"107671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Efficacy and mechanism of actions of natural antimicrobial drugs"],"prefix":"10.1016","volume":"216","author":[{"given":"Ling","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2020.107671_bb0005","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1128\/AAC.31.7.1093","article-title":"Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032","volume":"31","author":"Allen","year":"1987","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0010","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13613-020-00707-2","article-title":"Pharmacokinetics of tigecycline in critically ill patients with liver failure defined by maximal liver function capacity test (LiMAx)","volume":"10","author":"Alraish","year":"2020","journal-title":"Annals of Intensive Care"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0015","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2165\/00003495-200868050-00006","article-title":"Dalbavancin","volume":"68","author":"Anderson","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0020","author":"Anidulafungin FDA Label"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0025","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1128\/AAC.46.2.451-457.2002","article-title":"Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases","volume":"46","author":"Arathoon","year":"2002","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0030","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1056\/NEJMoa1011138","article-title":"Genetic basis for in vivo daptomycin resistance in enterococci","volume":"365","author":"Arias","year":"2011","journal-title":"The New England Journal of Medicine"},{"issue":"Suppl. 2","key":"10.1016\/j.pharmthera.2020.107671_bb0035","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1093\/cid\/cis358","article-title":"Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis","volume":"55","author":"Artsimovitch","year":"2012","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0040","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0009-9236(98)90044-3","article-title":"Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria","volume":"63","author":"Ashton","year":"1998","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2020.107671_bb0045","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0213-005X(17)30031-9","article-title":"Dalbavancin: Pharmacokinetic and pharmacodynamic parameters","volume":"35","author":"Azanza","year":"2017","journal-title":"Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0050","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1039\/b602241n","article-title":"The value of natural products to future pharmaceutical discovery","volume":"24","author":"Baker","year":"2007","journal-title":"Natural Product Reports"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0055","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12223-017-0496-9","article-title":"Andrographolide: Antibacterial activity against common bacteria of human health concern and possible mechanism of action","volume":"62","author":"Banerjee","year":"2017","journal-title":"Folia Microbiologia (Praha)"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0060","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1128\/AAC.44.1.78-87.2000","article-title":"Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies","volume":"44","author":"Barnett","year":"2000","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0065","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2217\/fmb.10.138","article-title":"ATLAS trials: Efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections","volume":"5","author":"Barriere","year":"2010","journal-title":"Future Microbiology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0070","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1007\/s00134-015-4021-9","article-title":"Is empiric daptomycin effective in reducing mortality in Staphylococcus aureus bacteraemia? A real-life experience","volume":"41","author":"Bassetti","year":"2015","journal-title":"Intensive Care Medicine"},{"issue":"Suppl. 2","key":"10.1016\/j.pharmthera.2020.107671_bb0075","first-page":"5","article-title":"Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies","volume":"68","author":"Bassetti","year":"2013","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0080","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1007\/s00134-017-4878-x","article-title":"Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: A visionary approach","volume":"43","author":"Bassetti","year":"2017","journal-title":"Intensive Care Medicine"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0085","doi-asserted-by":"crossref","first-page":"5369","DOI":"10.1128\/AAC.00760-10","article-title":"Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing","volume":"54","author":"Belley","year":"2010","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0090","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1128\/AAC.00766-08","article-title":"Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro","volume":"53","author":"Belley","year":"2009","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0095","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/0036554021000026958","article-title":"Lack of effect of food on the bioavailability of a new ketolide antibacterial, telithromycin","volume":"34","author":"Bhargava","year":"2002","journal-title":"Scandinavian Journal of Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0100","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.diagmicrobio.2004.06.007","article-title":"Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects","volume":"50","author":"Bhavnani","year":"2004","journal-title":"Diagnostic Microbiology and Infectious Disease"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0105","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1093\/jac\/dkw315","article-title":"Comparative in vitro activities of ceftaroline and ceftriaxone against bacterial pathogens associated with respiratory tract infections: Results from the AWARE surveillance study","volume":"71","author":"Biedenbach","year":"2016","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0110","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jhin.2018.12.018","article-title":"Effect of using fidaxomicin on recurrent Clostridium difficile infection","volume":"102","author":"Biggs","year":"2019","journal-title":"The Journal of Hospital Infection"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0115","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0378-1097(97)00013-X","article-title":"Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases","volume":"148","author":"Bonomo","year":"1997","journal-title":"FEMS Microbiology Letters"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000669","article-title":"Chloroquine and its derivatives exacerbate B19V-associated anemia by promoting viral replication","volume":"4","author":"B\u00f6nsch","year":"2010","journal-title":"PLoS Neglected Tropical Diseases"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0125","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s00580-012-1539-x","article-title":"Acute and subacute toxicity study of andrographolide bioactive in rodents: Evidence for the medicinal use as an alternative medicine","volume":"22","author":"Bothiraja","year":"2013","journal-title":"Comparative Clinical Pathology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0130","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0135","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/hep.22620","article-title":"Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases","volume":"49","author":"Brinker","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0140","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004404","article-title":"Hidden killers: Human fungal infections","volume":"4","author":"Brown","year":"2012","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0145","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1592\/phco.29.3.347","article-title":"Extremely low excretion of daptomycin into breast milk of a nursing mother with methicillin-resistant Staphylococcus aureus pelvic inflammatory disease","volume":"29","author":"Buitrago","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0150","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(19)32982-4","article-title":"Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: An open-label, pragmatic, randomised controlled trial","volume":"395","author":"Butler","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0155","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/jac\/44.2.179","article-title":"In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic","volume":"44","author":"Candiani","year":"1999","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0160","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1128\/AAC.34.6.1220","article-title":"Lipoteichoic acid as a new target for activity of antibiotics: Mode of action of daptomycin (LY146032)","volume":"34","author":"Canepari","year":"1990","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0165","author":"Caspofungin FDA label"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2020.107671_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199936001-00001","article-title":"Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers","volume":"36","author":"Cass","year":"1999","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0175","author":"Ceftaroline Fosamil FDA Label"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0180","author":"Ceftolozane\/Tazobactam FDA Label"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0185","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/jac\/44.5.697","article-title":"In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients","volume":"44","author":"Ch\u00e1vez","year":"1999","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0190","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.3109\/00498254.2015.1042537","article-title":"Organic anion-transporting polypeptides contribute to the hepatic uptake of berberine","volume":"45","author":"Chen","year":"2015","journal-title":"Xenobiotica"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0195","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.micres.2016.03.003","article-title":"The effect of berberine hydrochloride on Enterococcus faecalis biofilm formation and dispersion in vitro","volume":"186\u2013187","author":"Chen","year":"2016","journal-title":"Microbiological Research"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0200","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1111\/1750-3841.14372","article-title":"Baicalin, Baicalein, and Lactobacillus Rhamnosus JB3 Alleviated Helicobacter pylori infections in vitro and in vivo","volume":"83","author":"Chen","year":"2018","journal-title":"Journal of Food Science"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0205","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3389\/fphar.2018.00104","article-title":"A mechanistic overview of triptolide and celastrol, natural products from Tripterygium wilfordii Hook F","volume":"9","author":"Chen","year":"2018","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0210","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1039\/C3OB42428F","article-title":"Anti-cooperative ligand binding and dimerisation in the glycopeptide antibiotic dalbavancin","volume":"12","author":"Cheng","year":"2014","journal-title":"Organic & Biomolecular Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0215","doi-asserted-by":"crossref","first-page":"102953","DOI":"10.1016\/j.bioorg.2019.102953","article-title":"Discovery of Baicalin as NDM-1 inhibitor: Virtual screening, biological evaluation and molecular simulation","volume":"88","author":"Cheng","year":"2019","journal-title":"Bioorganic Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0220","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa1909666","article-title":"Family history of gastric cancer and Helicobacter pylori treatment","volume":"382","author":"Choi","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0225","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1472-6882-14-89","article-title":"Role of berberine in anti-bacterial as a high-affinity LPS antagonist binding to TLR4\/MD-2 receptor","volume":"14","author":"Chu","year":"2014","journal-title":"BMC Complementary and Alternative Medicine"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0230","doi-asserted-by":"crossref","first-page":"263630","DOI":"10.1155\/2015\/263630","article-title":"Role of baicalin in anti-Influenza Virus A as a potent inducer of IFN-gamma","volume":"2015","author":"Chu","year":"2015","journal-title":"BioMed Research International"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0235","doi-asserted-by":"crossref","first-page":"24748","DOI":"10.1038\/srep24748","article-title":"Role of berberine in the treatment of methicillin-resistant Staphylococcus aureus infections","volume":"6","author":"Chu","year":"2016","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0240","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1136\/jim-2016-000117","article-title":"Mechanisms of ertapenem resistance in Enterobacteriaceae isolates in a tertiary university hospital","volume":"64","author":"Chung","year":"2016","journal-title":"Journal of Investigative Medicine"},{"key":"10.1016\/j.pharmthera.2020.107671_bb6000","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1128\/AAC.00424-08","article-title":"Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men","volume":"52","author":"Cirillo","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0245","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1128\/AAC.01602-10","article-title":"Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria","volume":"55","author":"Clark","year":"2011","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0250","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1586\/14787210.3.2.191","article-title":"Zanamivir: An influenza virus neuraminidase inhibitor","volume":"3","author":"Colman","year":"2005","journal-title":"Expert Review of Anti-Infective Therapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0255","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciu778","article-title":"Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: The SOLO II noninferiority study","volume":"60","author":"Corey","year":"2015","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0260","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","article-title":"Single-dose oritavancin in the treatment of acute bacterial skin infections","volume":"370","author":"Corey","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0265","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","article-title":"Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: A double-blind, non-inferiority, randomised controlled trial","volume":"12","author":"Cornely","year":"2012","journal-title":"The Lancet Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0270","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1517\/14740338.2011.557062","article-title":"Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases","volume":"10","author":"Cornely","year":"2011","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0275","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1749-6632.2001.tb11356.x","article-title":"Medicinals for the millennia: The historical record","volume":"953","author":"Cragg","year":"2001","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2020.107671_bb0280","first-page":"8","article-title":"Natural product drug discovery in the next millennium","volume":"39","author":"Cragg","year":"2001","journal-title":"Pharmaceutical Biology"},{"issue":"Suppl. 2","key":"10.1016\/j.pharmthera.2020.107671_bb0285","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1093\/cid\/cis499","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection: Meta-analysis of pivotal randomized controlled trials","volume":"55","author":"Crook","year":"2012","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0290","author":"Dalbavancin FDA Label"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0295","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.2165\/00003495-200363240-00005","article-title":"Enfuvirtide","volume":"63","author":"Dando","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0300","first-page":"383","article-title":"Helicobacter pylori infection and antibiotic resistance: A WHO high priority?","volume":"14","author":"Dang","year":"2017","journal-title":"Nature Reviews: Gastroenterology & Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2020.107671_bb0305","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-199936001-00005","article-title":"The low potential for drug interactions with zanamivir","volume":"36","author":"Daniel","year":"1999","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0310","author":"Daptomycin FDA Label"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0315","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1128\/AAC.01529-07","article-title":"Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa","volume":"52","author":"Davies","year":"2008","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0320","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jchromb.2019.03.036","article-title":"Determination of daptomycin in human plasma and breast milk by UPLC\/MS-MS","volume":"1116","author":"Dei Cas","year":"2019","journal-title":"Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0325","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10295-013-1325-z","article-title":"Importance of microbial natural products and the need to revitalize their discovery","volume":"41","author":"Demain","year":"2014","journal-title":"Journal of Industrial Microbiology & Biotechnology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0330","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4103\/1947-2714.183015","article-title":"A novel way of treating multidrug-resistant enterococci","volume":"8","author":"Desai","year":"2016","journal-title":"North American Journal of Medical Sciences"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0335","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1039\/b914961a","article-title":"Natural products as antifungal agents against clinically relevant pathogens","volume":"27","author":"Di Santo","year":"2010","journal-title":"Natural Product Reports"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0340","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3390\/metabo2020303","article-title":"A historical overview of natural products in drug discovery","volume":"2","author":"Dias","year":"2012","journal-title":"Metabolites"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0345","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1128\/AAC.41.5.1069","article-title":"Effect of food intake on pharmacokinetics of oral artemisinin in healthy Vietnamese subjects","volume":"41","author":"Dien","year":"1997","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0350","doi-asserted-by":"crossref","first-page":"113691","DOI":"10.1016\/j.bcp.2019.113691","article-title":"Resveratrol promotes HSV-2 replication by increasing histone acetylation and activating NF-\u03baB","volume":"171","author":"Ding","year":"2020","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0355","doi-asserted-by":"crossref","first-page":"10854","DOI":"10.1158\/0008-5472.CAN-05-1216","article-title":"Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo","volume":"65","author":"Disbrow","year":"2005","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0360","author":"Doripenem FDA Label"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0365","doi-asserted-by":"crossref","first-page":"103666","DOI":"10.1016\/j.jprot.2020.103666","article-title":"Proteomic investigation into the action mechanism of berberine against Streptococcus pyogenes","volume":"215","author":"Du","year":"2020","journal-title":"Journal of Proteomics"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0370","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1086\/652655","article-title":"Use of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus","volume":"50","author":"Dulek","year":"2010","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0375","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40264-015-0374-9","article-title":"Safety of Dalbavancin in the treatment of skin and skin structure infections: A pooled analysis of randomized, comparative studies","volume":"39","author":"Dunne","year":"2016","journal-title":"Drug Safety"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0380","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijantimicag.2016.04.022","article-title":"Safety of treatment with high-dose daptomycin in 102 patients with infective endocarditis","volume":"48","author":"Durante-Mangoni","year":"2016","journal-title":"International Journal of Antimicrobial Agents"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0385","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1177\/0091270004265646","article-title":"Single-dose pharmacokinetics of daptomycin in young and geriatric volunteers","volume":"44","author":"Dvorchik","year":"2004","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0390","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","article-title":"Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects","volume":"47","author":"Dvorchik","year":"2003","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0395","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1098\/rstb.2001.1021","article-title":"Zanamivir: From drug design to the clinic","volume":"356","author":"Elliott","year":"2001","journal-title":"Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0400","series-title":"Bacterial infections and cancer. EMBO reports","volume":"19","author":"van Elsland","year":"2018"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0405","author":"Enfuvirtide FDA Label"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0410","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0732-8893(96)00202-7","article-title":"Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp","volume":"26","author":"Ernst","year":"1996","journal-title":"Diagnostic Microbiology and Infectious Disease"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0415","author":"Ertapenem Sodium FDA Label"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0420","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1186\/2047-783X-15-12-533","article-title":"Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin","volume":"15","author":"Estes","year":"2010","journal-title":"European Journal of Medical Research"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0425","doi-asserted-by":"crossref","first-page":"104019","DOI":"10.1016\/j.micpath.2020.104019","article-title":"The oncogenic roles of bacterial infections in development of cancer","volume":"141","author":"Eyvazi","year":"2020","journal-title":"Microbial Pathogenesis"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0430","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1365-2036.2008.03642.x","article-title":"Meta-analysis: Ertapenem for complicated intra-abdominal infections","volume":"27","author":"Falagas","year":"2008","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0435","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1128\/AAC.48.5.1882-1884.2004","article-title":"Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003","volume":"48","author":"Farrell","year":"2004","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0440","doi-asserted-by":"crossref","first-page":"12155","DOI":"10.1038\/srep12155","article-title":"Transforming berberine into its intestine-absorbable form by the gut microbiota","volume":"5","author":"Feng","year":"2015","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0445","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1439-0507.2003.00838.x","article-title":"Inhibition of human pathogenic fungi by ethnobotanically selected plant extracts","volume":"46","author":"Ficker","year":"2003","journal-title":"Mycoses"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0450","author":"Fidaxomicin FDA Label"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0455","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/apt.12814","article-title":"Review article: The epidemiology and prevention of gastric cancer","volume":"40","author":"Fock","year":"2014","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0460","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1742-1241.2004.00344.x","article-title":"Telithromycin for the treatment of acute exacerbations of chronic bronchitis","volume":"59","author":"Fogarty","year":"2005","journal-title":"International Journal of Clinical Practice"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0465","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2334-5-43","article-title":"Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: An open-label, multicenter study","volume":"5","author":"Fogarty","year":"2005","journal-title":"BMC Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0470","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0475","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1128\/AAC.00836-09","article-title":"Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients","volume":"54","author":"Frasca","year":"2010","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0480","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1540-9740.2006.05774.x","article-title":"Retapamulin ointment twice daily for 5 days vs oral cephalexin twice daily for 10 days for empiric treatment of secondarily infected traumatic lesions of the skin","volume":"5","author":"Free","year":"2006","journal-title":"Skinmed"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0485","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cmi.2017.10.008","article-title":"The ClosER study: Results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes, 2011\u20132014","volume":"24","author":"Freeman","year":"2018","journal-title":"Clinical Microbiology and Infection"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0490","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2165\/00002018-199921040-00003","article-title":"Zanamivir: A review of clinical safety","volume":"21","author":"Freund","year":"1999","journal-title":"Drug Safety"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0495","series-title":"Baicalin suppresses NLRP3 inflammasome and nuclear factor-kappa B (NF-\u03baB) signaling during Haemophilus parasuis infection","first-page":"80","volume":"47","author":"Fu","year":"2016"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0500","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1469-0691.2004.01051.x","article-title":"Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres","volume":"11","author":"Gales","year":"2005","journal-title":"Clinical Microbiology and Infection"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0505","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.cmi.2018.12.007","article-title":"Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: A retrospective cohort study","volume":"25","author":"Gentry","year":"2019","journal-title":"Clinical Microbiology and Infection"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0510","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1592\/phco.30.1.35","article-title":"Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin","volume":"30","author":"Goldberg","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0515","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1128\/AAC.47.6.1968-1971.2003","article-title":"In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria","volume":"47","author":"Goldstein","year":"2003","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0520","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1128\/AAC.00625-11","article-title":"Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection","volume":"55","author":"Goldstein","year":"2011","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0525","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1128\/AAC.00407-12","article-title":"Anti-Helicobacter pylori potential of artemisinin and its derivatives","volume":"56","author":"Goswami","year":"2012","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0530","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMc066372","article-title":"Telithromycin and acute liver failure","volume":"355","author":"Graham","year":"2006","journal-title":"The New England Journal of Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107671_bb0535","first-page":"297","article-title":"Fidaxomicin: New therapy for Clostridium difficile-associated diarrhea","volume":"46","author":"Grant","year":"2011","journal-title":"Formulary (Cleveland, Ohio)"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0540","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1128\/AAC.43.4.830","article-title":"LY303366 exhibits rapid and potent fungicidal activity in flow cytometric assays of yeast viability","volume":"43","author":"Green","year":"1999","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0545","series-title":"Ca(2+)-Daptomycin targets cell wall biosynthesis by forming a tripartite complex with undecaprenyl-coupled intermediates and membrane lipids","first-page":"1455","volume":"11","author":"Grein","year":"2020"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0550","first-page":"2147","article-title":"Preliminary study of effects of andrographolide on Staphylococcus epidermidis biofilms","volume":"37","author":"Guan","year":"2012","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0555","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1086\/314440","article-title":"Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus","volume":"178","author":"Gubareva","year":"1998","journal-title":"The Journal of Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0560","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.vetmic.2014.09.021","article-title":"Andrographolide interferes quorum sensing to reduce cell damage caused by avian pathogenic Escherichia coli","volume":"174","author":"Guo","year":"2014","journal-title":"Veterinary Microbiology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0565","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00228-011-1108-2","article-title":"Repeated administration of berberine inhibits cytochromes P450 in humans","volume":"68","author":"Guo","year":"2012","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0570","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3109\/00498254.2011.597456","article-title":"CYP2D plays a major role in berberine metabolism in liver of mice and humans","volume":"41","author":"Guo","year":"2011","journal-title":"Xenobiotica"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0575","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00705-016-3166-3","article-title":"Broad-spectrum antiviral properties of andrographolide","volume":"162","author":"Gupta","year":"2017","journal-title":"Archives of Virology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0580","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1128\/AAC.41.11.2339","article-title":"Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872)","volume":"41","author":"Hajdu","year":"1997","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0585","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1055\/s-0029-1185943","article-title":"Effects of baicalin on Chlamydia trachomatis infection in vitro","volume":"76","author":"Hao","year":"2010","journal-title":"Journal of Planta Medica"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0590","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrd4510","article-title":"The re-emergence of natural products for drug discovery in the genomics era","volume":"14","author":"Harvey","year":"2015","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0595","doi-asserted-by":"crossref","first-page":"219","DOI":"10.7164\/antibiotics.55.219","article-title":"Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus","volume":"55","author":"Hatano","year":"2002","journal-title":"Journal of Antibiotics (Tokyo)"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0600","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/00003088-199937060-00003","article-title":"Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802","volume":"37","author":"He","year":"1999","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0605","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1128\/AAC.01623-06","article-title":"In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004","volume":"51","author":"Hecht","year":"2007","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0610","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.pharmthera.2013.12.001","article-title":"Artemisinins: Pharmacological actions beyond anti-malarial","volume":"142","author":"Ho","year":"2014","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0615","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1124\/dmd.107.015735","article-title":"Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects","volume":"35","author":"Hoffmann","year":"2007","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0620","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.gastro.2017.04.022","article-title":"Global prevalence of Helicobacter pylori infection: Systematic review and meta-analysis","volume":"153","author":"Hooi","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0625","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.2174\/138955709789957387","article-title":"Mutilins derivatives: From veterinary to human-used antibiotics","volume":"9","author":"Hu","year":"2009","journal-title":"Mini Reviews in Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0630","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/jac\/48.3.361","article-title":"Epigallocatechin gallate synergy with ampicillin\/sulbactam against 28 clinical isolates of methicillin-resistant Staphylococcus aureus","volume":"48","author":"Hu","year":"2001","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0635","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.taap.2017.03.016","article-title":"Baicalin benefits the anti-HBV therapy via inhibiting HBV viral RNAs","volume":"323","author":"Huang","year":"2017","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0640","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/1871526514666140827102154","article-title":"Antiviral herbs\u2014Present and future","volume":"14","author":"Huang","year":"2014","journal-title":"Infectious Disorders Drug Targets"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0645","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbrc.2020.04.034","article-title":"Kinase inhibitor roscovitine as a PB2 cap-binding inhibitor against influenza a virus replication","volume":"526","author":"Huang","year":"2020","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0650","series-title":"Inhibition of berberine hydrochloride on Candida albicans biofilm formation","author":"Huang","year":"2020"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0655","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.3748\/wjg.v21.i14.4225","article-title":"Inhibitory effects of emodin, baicalin, schizandrin and berberine on hefA gene: Treatment of Helicobacter pylori-induced multidrug resistance","volume":"21","author":"Huang","year":"2015","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0660","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1331\/1544345054475504","article-title":"New drugs: Exenatide, pramlintide acetate, and micafungin sodium","volume":"45","author":"Hussar","year":"2005","journal-title":"Journal of the American Pharmaceutical Association"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0665","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.mib.2019.10.008","article-title":"Antibiotics: Past, present and future","volume":"51","author":"Hutchings","year":"2019","journal-title":"Current Opinion in Microbiology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0670","first-page":"33","article-title":"Berberine and barberry (Berberis vulgaris): A clinical review","author":"Imenshahidi","year":"2019","journal-title":"Journal of Phytotherapy Research"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0675","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1056\/NEJMoa054408","article-title":"Ertapenem versus cefotetan prophylaxis in elective colorectal surgery","volume":"355","author":"Itani","year":"2006","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0680","doi-asserted-by":"crossref","first-page":"g2545","DOI":"10.1136\/bmj.g2545","article-title":"Oseltamivir for influenza in adults and children: Systematic review of clinical study reports and summary of regulatory comments","volume":"348","author":"Jefferson","year":"2014","journal-title":"Bmj"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0685","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12272-018-1022-6","article-title":"The inhibitory effect of sodium baicalin on oseltamivir-resistant influenza A virus via reduction of neuraminidase activity","volume":"41","author":"Jin","year":"2018","journal-title":"Archives of Pharmacal Research"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0690","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1517\/14656566.4.5.807","article-title":"Caspofungin: First approved agent in a new class of antifungals","volume":"4","author":"Johnson","year":"2003","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0695","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1128\/AAC.05098-14","article-title":"Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide","volume":"59","author":"Jones","year":"2015","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0700","first-page":"225","article-title":"New developments in the treatment of acute bacterial skin and skin structure infections: Considerations for the effective use of dalbavancin","volume":"12","author":"Juul","year":"2016","journal-title":"Therapeutics and Clinical Risk Management"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0705","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1086\/313696","article-title":"Short-term treatment with zanamivir to prevent influenza: Results of a placebo-controlled study","volume":"30","author":"Kaiser","year":"2000","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0710","first-page":"94","article-title":"Drug interactions of micafungin in vitro","volume":"50","author":"Kaneko","year":"2002","journal-title":"Japanese Journal of Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0715","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.vetmic.2005.02.011","article-title":"Biofilm formation is prevalent among field isolates of Actinobacillus pleuropneumoniae","volume":"108","author":"Kaplan","year":"2005","journal-title":"Veterinary Microbiology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0720","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1128\/AAC.00476-08","article-title":"In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile","volume":"52","author":"Karlowsky","year":"2008","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0725","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.diagmicrobio.2017.01.006","article-title":"In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015","volume":"87","author":"Karlowsky","year":"2017","journal-title":"Diagnostic Microbiology and Infectious Disease"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0730","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10295-015-1723-5","article-title":"Natural product discovery: Past, present, and future","volume":"43","author":"Katz","year":"2016","journal-title":"Journal of Industrial Microbiology & Biotechnology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0735","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1086\/518385","article-title":"Zanamivir treatment is equally effective for both influenza A and influenza B","volume":"44","author":"Kawai","year":"2007","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0740","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.2165\/00003495-200868140-00007","article-title":"Doripenem: A review of its use in the treatment of bacterial infections","volume":"68","author":"Keam","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0745","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.2165\/00003495-200363200-00008","article-title":"Caspofungin: A review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis","volume":"63","author":"Keating","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0750","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/3293","article-title":"Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry","volume":"4","author":"Kilby","year":"1998","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0755","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1089\/088922202760072294","article-title":"The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults","volume":"18","author":"Kilby","year":"2002","journal-title":"AIDS Research and Human Retroviruses"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0760","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jmb.2008.01.031","article-title":"Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus","volume":"377","author":"Kim","year":"2008","journal-title":"Journal of Molecular Biology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0765","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jmb.2009.06.033","article-title":"Oritavancin binds to isolated protoplast membranes but not intact protoplasts of Staphylococcus aureus","volume":"391","author":"Kim","year":"2009","journal-title":"Journal of Molecular Biology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0770","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1128\/AAC.43.5.1170","article-title":"In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates","volume":"43","author":"Kohler","year":"1999","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0775","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1016\/j.bbamem.2014.05.013","article-title":"The role of spontaneous lipid curvature in the interaction of interfacially active peptides with membranes","volume":"1838","author":"Koller","year":"2014","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0780","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/j.1365-2133.2008.08485.x","article-title":"Efficacy and safety of retapamulin ointment as treatment of impetigo: Randomized double-blind multicentre placebo-controlled trial","volume":"158","author":"Koning","year":"2008","journal-title":"The British Journal of Dermatology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0785","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/myc.12641","article-title":"Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies","volume":"60","author":"Kontoyiannis","year":"2017","journal-title":"Mycoses"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0790","first-page":"62","article-title":"Fidaxomicin and OP-1118 inhibit clostridium difficile toxin A- and B-mediated inflammatory responses via inhibition of NF-\u03baB activity","author":"Koon","year":"2018","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0795","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4269\/ajtmh.1999.60.244","article-title":"The pharmacokinetics of artemisinin after administration of two different suppositories to healthy Vietnamese subjects","volume":"60","author":"Koopmans","year":"1999","journal-title":"The American Journal of Tropical Medicine and Hygiene"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0800","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1128\/AAC.00019-10","article-title":"Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae","volume":"54","author":"Kosowska-Shick","year":"2010","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0805","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jpba.2018.09.044","article-title":"Determination of total and free ceftolozane and tazobactam in human plasma and interstitial fluid by HPLC-UV","volume":"163","author":"Kratzer","year":"2019","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0810","first-page":"4","article-title":"Structure-based design of enzyme inhibitors and receptor ligands","volume":"1","author":"Kubinyi","year":"1998","journal-title":"Current Opinion in Drug Discovery & Development"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0815","first-page":"97","article-title":"Telithromycin in acute exacerbations of asthma","volume":"355","author":"Kuramochi","year":"2006","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0820","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/bph.12440","article-title":"Andrographolide exerts anti-hepatitis C virus activity by up-regulating haeme oxygenase-1 via the p38 MAPK\/Nrf2 pathway in human hepatoma cells","volume":"171","author":"Lee","year":"2014","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0825","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1517\/13543784.15.3.211","article-title":"Recent developments in antibacterial drug discovery: Microbe-derived natural products\u2014from collection to the clinic","volume":"15","author":"Leeds","year":"2006","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0830","first-page":"5041","article-title":"Baicalin inhibits influenza virus A replication via activation of type I IFN signaling by reducing miR-146a","volume":"20","author":"Li","year":"2019","journal-title":"Molecular Medicine Reports"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0835","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.3390\/v7082841","article-title":"The antiviral effect of baicalin on enterovirus 71 in vitro","volume":"7","author":"Li","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0840","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1128\/AAC.49.12.5182-5184.2005","article-title":"Antipneumococcal activity of dalbavancin compared to other agents","volume":"49","author":"Lin","year":"2005","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0845","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ejphar.2008.04.056","article-title":"Differential effects of triptolide and tetrandrine on activation of COX-2, NF-kappaB, and AP-1 and virus production in dengue virus-infected human lung cells","volume":"589","author":"Liou","year":"2008","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0850","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ijantimicag.2015.05.003","article-title":"Ceftolozane\/tazobactam and ceftazidime\/avibactam: Two novel \u03b2-lactam\/\u03b2-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections","volume":"46","author":"Liscio","year":"2015","journal-title":"International Journal of Antimicrobial Agents"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0855","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1211\/0022357001773922","article-title":"Baicalin synergy with beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus and other beta-lactam-resistant strains of S. aureus","volume":"52","author":"Liu","year":"2000","journal-title":"The Journal of Pharmacy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0860","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1211\/0022357001773922","article-title":"Baicalin synergy with beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus and other beta-lactam-resistant strains of S. aureus","volume":"52","author":"Liu","year":"2000","journal-title":"The Journal of Pharmacy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0865","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/01480541003774358","article-title":"Triptolide induces adverse effect on reproductive parameters of female Sprague-Dawley rats","volume":"34","author":"Liu","year":"2011","journal-title":"Drug and Chemical Toxicology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0870","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2165\/11635660-000000000-00000","article-title":"Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections","volume":"72","author":"Lodise","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0875","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1128\/AAC.01443-07","article-title":"OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection","volume":"53","author":"Louie","year":"2009","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0880","first-page":"868","article-title":"Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: A phase III, prospective, multicenter, randomized, double-blind, noninferiority study","volume":"30","author":"Lucasti","year":"2008","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0885","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1128\/AAC.01710-08","article-title":"Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II","volume":"53","author":"Lunde","year":"2009","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0890","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1093\/jac\/dkv211","article-title":"Induced tigecycline resistance in Streptococcus pneumoniae mutants reveals mutations in ribosomal proteins and rRNA","volume":"70","author":"Lupien","year":"2015","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0895","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.biopha.2018.10.054","article-title":"A proteomic analysis of the anti-dengue virus activity of andrographolide","volume":"109","author":"Paemanee","year":"2019","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0900","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1211\/jpp.61.07.0001","article-title":"Neuropharmacological and pharmacokinetic properties of berberine: A review of recent research","volume":"61","author":"Ye","year":"2009","journal-title":"The Journal of Pharmacy and Pharmacology"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107671_bb0905","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1124\/dmd.113.054056","article-title":"Assessment of the roles of P-glycoprotein and cytochrome P450 in triptolide-induced liver toxicity in sandwich-cultured rat hepatocyte model","volume":"41","author":"M","year":"2013","journal-title":"Journal of Drug & Disposition"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0910","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1586\/17512433.2015.986461","article-title":"Ceftaroline fosamil for treating skin and skin structure infections or community-acquired pneumonia in patients with renal insufficiency","volume":"8","author":"Maggiore","year":"2015","journal-title":"Expert Review of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0915","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s40265-014-0295-4","article-title":"Oritavancin: First global approval","volume":"74","author":"Markham","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0920","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1093\/jac\/dkw269","article-title":"Tissue pharmacokinetics of telavancin in healthy volunteers: A microdialysis study","volume":"71","author":"Matzneller","year":"2016","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0925","article-title":"Micafungin, an anti-fungal agent, exerts potent effects despite high serum protein binding","volume":"15","author":"Mayuki","year":"2008","journal-title":"Journal of the Japanese Society of Intensive Care"},{"issue":"Suppl. 5","key":"10.1016\/j.pharmthera.2020.107671_bb0930","doi-asserted-by":"crossref","first-page":"S333","DOI":"10.1086\/431674","article-title":"The pharmacokinetic and pharmacodynamic profile of tigecycline","volume":"41","author":"Meagher","year":"2005","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0935","doi-asserted-by":"crossref","DOI":"10.1038\/d41586-019-02316-x","article-title":"Alarming surge in drug-resistant HIV uncovered","author":"Mega","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0940","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1128\/AAC.42.3.640","article-title":"Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection","volume":"42","author":"Mendel","year":"1998","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0945","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/jac\/dkh504","article-title":"Initial results from a longitudinal international surveillance programme for anidulafungin (2003)","volume":"54","author":"Messer","year":"2004","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0950","author":"Micafungin FDA Label"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0955","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1128\/AAC.06349-11","article-title":"Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses","volume":"56","author":"Miller","year":"2012","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0960","doi-asserted-by":"crossref","first-page":"12447","DOI":"10.1128\/JVI.79.19.12447-12454.2005","article-title":"Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro","volume":"79","author":"Mink","year":"2005","journal-title":"Journal of Virology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0965","first-page":"e35","article-title":"Enfuvirtide and cutaneous injection-site reactions","volume":"11","author":"Mirza","year":"2012","journal-title":"Journal of Drugs in Dermatology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0970","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/jac\/dkp503","article-title":"Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae","volume":"65","author":"Moisan","year":"2010","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0975","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.tips.2016.05.001","article-title":"Natural products as a source for novel antibiotics","volume":"37","author":"Moloney","year":"2016","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0980","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1007\/s00134-014-3323-7","article-title":"Tigecycline use in critically ill patients: A multicentre prospective observational study in the intensive care setting","volume":"40","author":"Montravers","year":"2014","journal-title":"Intensive Care Medicine"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0985","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1056\/NEJMp058291","article-title":"Oseltamivir resistance\u2014Disabling our influenza defenses","volume":"353","author":"Moscona","year":"2005","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0990","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1128\/AAC.00296-10","article-title":"Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa","volume":"54","author":"Moy\u00e1","year":"2010","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb0995","first-page":"E7077","article-title":"Daptomycin inhibits cell envelope synthesis by interfering with fluid membrane microdomains","volume":"113","author":"M\u00fcller","year":"2016","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1000","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1128\/AAC.02663-14","article-title":"Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin","volume":"59","author":"M\u00fcnch","year":"2015","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1005","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1128\/AAC.49.1.220-229.2005","article-title":"Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects","volume":"49","author":"Muralidharan","year":"2005","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1010","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/jac\/dkp493","article-title":"AmpC induction by ceftaroline","volume":"65","author":"Mushtaq","year":"2010","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1015","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/jac\/dkh401","article-title":"Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods","volume":"54","author":"Mushtaq","year":"2004","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1020","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/jac\/dkm150","article-title":"In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes","volume":"60","author":"Mushtaq","year":"2007","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1025","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1128\/AAC.01121-07","article-title":"Transcriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarization","volume":"52","author":"Muthaiyan","year":"2008","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1030","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.molstruc.2006.09.032","article-title":"Interaction of zanamivir with DNA and RNA: Models for drug\u2013DNA and drug\u2013RNA bindings","volume":"830","author":"Nafisi","year":"2007","journal-title":"Journal of Molecular Structure"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1035","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/jac\/dkt534","article-title":"Antiviral activity of baicalin against influenza virus H1N1-pdm09 is due to modulation of NS1-mediated cellular innate immune responses","volume":"69","author":"Nayak","year":"2014","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1040","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/jac\/dks112","article-title":"Reconstitution of high-level micafungin resistance detected in a clinical isolate of Candida glabrata identifies functional homozygosity in glucan synthase gene expression","volume":"67","author":"Niimi","year":"2012","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1045","first-page":"255","article-title":"General pharmacological effects of tazobactam metabolite M-1","volume":"42","author":"Nishimori","year":"1994","journal-title":"Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1050","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF03189697","article-title":"Metabolic fate of Qinghaosu in rats; a new TLC densitometric method for its determination in biological material","volume":"10","author":"Niu","year":"1985","journal-title":"European Journal of Drug Metabolism and Pharmacokinetics"},{"issue":"Suppl. 2","key":"10.1016\/j.pharmthera.2020.107671_bb1055","first-page":"23","article-title":"Pharmacokinetics and pharmacodynamics of ertapenem: An overview for clinicians","volume":"53","author":"Nix","year":"2004","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1060","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/00365540110077443","article-title":"Efficacy of short-course therapy with the ketolide telithromycin compared with 10 days of penicillin V for the treatment of pharyngitis\/tonsillitis","volume":"33","author":"Norrby","year":"2001","journal-title":"Scandinavian Journal of Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1065","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1128\/AAC.48.10.3677-3683.2004","article-title":"Ketolide antimicrobial activity persists after disruption of interactions with domain II of 23S rRNA","volume":"48","author":"Novotny","year":"2004","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1070","series-title":"Tackling drug-resistant infections globally: Final report and recommendations","author":"O\u2019Neill","year":"2016"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1075","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1128\/AAC.48.5.1912-1915.2004","article-title":"In vitro activity of anidulafungin against selected clinically important mold isolates","volume":"48","author":"Odabasi","year":"2004","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1080","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00288-18","article-title":"The artemisinin derivative artemisone is a potent inhibitor of human cytomegalovirus replication","volume":"62","author":"Oiknine-Djian","year":"2018","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1085","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00705-018-4083-4","article-title":"Baicalein and baicalin as Zika virus inhibitors","volume":"164","author":"Oo","year":"2019","journal-title":"Archives of Virology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1090","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000107776","article-title":"Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: A randomized, observer-blinded, noninferiority study","volume":"215","author":"Oranje","year":"2007","journal-title":"Dermatology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1095","author":"Oritavancin FDA Label"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1100","author":"Oseltamivir FDA Label"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1105","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1128\/AAC.47.10.3149-3154.2003","article-title":"Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States","volume":"47","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1110","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1128\/AAC.00955-08","article-title":"Activity of anidulafungin in a murine model of Candida krusei infection: Evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels","volume":"53","author":"Ostrosky-Zeichner","year":"2009","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1115","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S0140-6736(15)00455-9","article-title":"2015 Nobel Prize goes to antiparasitic drug discoverers","volume":"386","author":"Owens","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1120","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.antiviral.2016.12.014","article-title":"Activity of andrographolide against dengue virus","volume":"139","author":"Panraksa","year":"2017","journal-title":"Antiviral Research"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1125","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1345\/aph.1C114","article-title":"Caspofungin acetate for treatment of invasive fungal infections","volume":"37","author":"Pacetti","year":"2003","journal-title":"The Annals of Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1130","doi-asserted-by":"crossref","first-page":"16194","DOI":"10.1038\/nmicrobiol.2016.194","article-title":"Staphylococcus aureus inactivates daptomycin by releasing membrane phospholipids","volume":"2","author":"Pader","year":"2016","journal-title":"Nature Microbiology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1135","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.bbrc.2006.07.014","article-title":"Hemin potentiates the anti-hepatitis C virus activity of the antimalarial drug artemisinin","volume":"348","author":"Paeshuyse","year":"2006","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1140","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ijantimicag.2019.06.025","article-title":"Off-label use of ceftaroline fosamil: A systematic review","volume":"54","author":"Pani","year":"2019","journal-title":"International Journal of Antimicrobial Agents"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1145","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jaad.2006.08.058","article-title":"Topical retapamulin ointment (1%, wt\/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: Results of a randomized controlled trial","volume":"55","author":"Parish","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1150","doi-asserted-by":"crossref","first-page":"551","DOI":"10.5021\/ad.2015.27.5.551","article-title":"In vitro antimicrobial activities of fusidic acid and retapamulin against mupirocin- and methicillin-resistant Staphylococcus aureus","volume":"27","author":"Park","year":"2015","journal-title":"Annals of Dermatology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1155","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.tube.2019.03.004","article-title":"Repurposing artemisinin as an anti-mycobacterial agent in synergy with rifampicin","volume":"115","author":"Patel","year":"2019","journal-title":"Tuberculosis (Edinburgh, Scotland)"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1160","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.cbi.2008.10.054","article-title":"Effects of Andrographis paniculata extract and Andrographolide on hepatic cytochrome P450 mRNA expression and monooxygenase activities after in vivo administration to rats and in vitro in rat and human hepatocyte cultures","volume":"179","author":"Pekthong","year":"2009","journal-title":"Chemico-Biological Interactions"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1165","first-page":"5217","article-title":"Antibacterial activity and mechanism of berberine against Streptococcus agalactiae","volume":"8","author":"Peng","year":"2015","journal-title":"International Journal of Clinical and Experimental Pathology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1170","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000066766","article-title":"Pharmacokinetics and absolute oral bioavailability of an 800-mg oral dose of telithromycin in healthy young and elderly volunteers","volume":"48","author":"Perret","year":"2002","journal-title":"Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1175","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1212\/01.wnl.0000247741.72466.8c","article-title":"Myasthenia gravis exacerbation or unmasking associated with telithromycin treatment","volume":"67","author":"Perrot","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1180","doi-asserted-by":"crossref","first-page":"5713703","DOI":"10.1155\/2018\/5713703","article-title":"Combination of epicatechin 3-gallate from euphorbia hirta and cefepime promotes potential synergistic eradication action against resistant clinical isolate of Pseudomonas aeruginosa","volume":"2018","author":"Perumal","year":"2018","journal-title":"Evidence-based Complementary and Alternative Medicine"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1185","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1159\/000445582","article-title":"Anidulafungin-induced suicidal erythrocyte death","volume":"38","author":"Peter","year":"2016","journal-title":"Cellular Physiology and Biochemistry"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1190","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1517\/13543784.13.9.1183","article-title":"Anidulafungin: An echinocandin antifungal","volume":"13","author":"Pfaller","year":"2004","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1195","doi-asserted-by":"crossref","first-page":"219S","DOI":"10.1592\/phco.20.14.219S.35046","article-title":"Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent","volume":"20","author":"Projan","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1200","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1205","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12977-018-0432-3","article-title":"Myricetin antagonizes semen-derived enhancer of viral infection (SEVI) formation and influences its infection-enhancing activity","volume":"15","author":"Ren","year":"2018","journal-title":"Retrovirology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1210","author":"Retapamulin FDA Label"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1215","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.antiviral.2005.07.005","article-title":"Effect of artemisinin\/artesunate as inhibitors of hepatitis B virus production in an \u201cin vitro\u201d replicative system","volume":"68","author":"Romero","year":"2005","journal-title":"Antiviral Research"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1220","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s40801-020-00188-6","article-title":"A two-dose oritavancin regimen using pharmacokinetic estimation analysis","volume":"7","author":"Rose","year":"2020","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1225","doi-asserted-by":"crossref","first-page":"12415","DOI":"10.1021\/acs.chemrev.7b00283","article-title":"Natural products as platforms to overcome antibiotic resistance","volume":"117","author":"Rossiter","year":"2017","journal-title":"Chemical Reviews"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1230","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1034\/j.1399-3062.2002.01004.x","article-title":"Safety and tolerability of caspofungin acetate in the treatment of fungal infections","volume":"4","author":"Sable","year":"2002","journal-title":"Transplant Infectious Disease"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1235","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.drudis.2007.10.010","article-title":"Plant-derived compounds in clinical trials","volume":"13","author":"Saklani","year":"2008","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1240","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.1128\/JB.00137-07","article-title":"Quorum-sensing regulation of the biofilm matrix genes (pel) of Pseudomonas aeruginosa","volume":"189","author":"Sakuragi","year":"2007","journal-title":"Journal of Bacteriology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1245","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1128\/AAC.05915-11","article-title":"Population pharmacokinetics of telavancin in healthy subjects and patients with infections","volume":"56","author":"Samara","year":"2012","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1250","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1053\/j.gastro.2018.07.007","article-title":"Prevalence of antibiotic resistance in Helicobacter pylori: A systematic review and meta-analysis in world health organization regions","volume":"155","author":"Savoldi","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1255","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1124\/dmd.106.014407","article-title":"The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3","volume":"35","author":"Seithel","year":"2007","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1260","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.2174\/1381612821666151002113426","article-title":"Natural products as promising therapeutics for treatment of influenza disease","volume":"21","author":"Sencanski","year":"2015","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1265","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.cell.2015.11.031","article-title":"A new golden age of natural products drug discovery","volume":"163","author":"Shen","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1270","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1007\/s10620-019-05977-w","article-title":"Baicalin is curative against rotavirus damp heat diarrhea by tuning colonic mucosal barrier and lung immune function","volume":"65","author":"Shen","year":"2020","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1275","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.biopha.2017.06.106","article-title":"Mechanism of berberine-mediated fluconazole-susceptibility enhancement in clinical fluconazole-resistant Candida tropicalis isolates","volume":"93","author":"Shi","year":"2017","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1280","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ejps.2018.11.010","article-title":"Organic cation transporter and multidrug and toxin extrusion 1 co-mediated interaction between metformin and berberine","volume":"127","author":"Shi","year":"2019","journal-title":"European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1285","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1128\/AAC.01045-07","article-title":"Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses","volume":"52","author":"Shue","year":"2008","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1290","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0166-3542(97)00065-X","article-title":"Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor","volume":"37","author":"Sidwell","year":"1998","journal-title":"Antiviral Research"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1295","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.2217\/fmb.15.67","article-title":"Natural products as a source of drug leads to overcome drug resistance","volume":"10","author":"Silver","year":"2015","journal-title":"Future Microbiology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1300","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijantimicag.2016.03.018","article-title":"In vitro activity of artemisone and artemisinin derivatives against extracellular and intracellular Helicobacter pylori","volume":"48","author":"Sisto","year":"2016","journal-title":"International Journal of Antimicrobial Agents"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1305","first-page":"290","article-title":"Evaluation of the synergistic effect of tomatidine with several antibiotics against standard and clinical isolates of Staphylococcus aureus, Enterococcus faecalis, Pseudomonas aeruginosa and Escherichia coli","volume":"16","author":"Soltani","year":"2017","journal-title":"Iranian Journal of Pharmaceutical Research"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1310","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1586\/14789072.2.5.685","article-title":"Telithromycin","volume":"2","author":"Spiers","year":"2004","journal-title":"Expert Review of Anti-Infective Therapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1315","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1086\/505494","article-title":"Tigecycline: A critical analysis","volume":"43","author":"Stein","year":"2006","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1320","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1128\/AAC.00563-06","article-title":"Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin","volume":"50","author":"Stevens","year":"2006","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1325","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1128\/AAC.46.3.739-745.2002","article-title":"Single- and multiple-dose pharmacokinetics of caspofungin in healthy men","volume":"46","author":"Stone","year":"2002","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1330","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1128\/AAC.48.3.815-823.2004","article-title":"Disposition of caspofungin: Role of distribution in determining pharmacokinetics in plasma","volume":"48","author":"Stone","year":"2004","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1335","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diagmicrobio.2003.09.004","article-title":"Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates","volume":"48","author":"Streit","year":"2004","journal-title":"Diagnostic Microbiology and Infectious Disease"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1340","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.diagmicrobio.2005.03.004","article-title":"Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens","volume":"53","author":"Streit","year":"2005","journal-title":"Diagnostic Microbiology and Infectious Disease"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1345","series-title":"Oseltamivir. In StatPearls","author":"Sur","year":"2020"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1350","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1046\/j.1365-2125.1999.00044.x","article-title":"Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin","volume":"48","author":"Svensson","year":"1999","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1355","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0009-9236(98)90149-7","article-title":"Artemisinin induces omeprazole metabolism in human beings","volume":"64","author":"Svensson","year":"1998","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1360","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3389\/fimmu.2018.01068","article-title":"Changing priorities in vaccinology: Antibiotic resistance moving to the top","volume":"9","author":"Tagliabue","year":"2018","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1365","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1128\/AAC.00164-13","article-title":"Methylation of 23S rRNA nucleotide G748 by RlmAII methyltransferase renders Streptococcus pneumoniae telithromycin susceptible","volume":"57","author":"Takaya","year":"2013","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1370","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/jac\/46.4.523","article-title":"Development of daptomycin for gram-positive infections","volume":"46","author":"Tally","year":"2000","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077969","article-title":"Tissue distribution of berberine and its metabolites after oral administration in rats","volume":"8","author":"Tan","year":"2013","journal-title":"PloS one"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1380","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1099\/mic.0.042010-0","article-title":"A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin","volume":"156","author":"Tannock","year":"2010","journal-title":"Microbiology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1385","author":"Telavancin FDA Label"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1390","author":"Telithromycin FDA Label"},{"issue":"Suppl. 2","key":"10.1016\/j.pharmthera.2020.107671_bb1395","first-page":"75","article-title":"Safety and tolerability of ertapenem","volume":"53","author":"Teppler","year":"2004","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1400","doi-asserted-by":"crossref","first-page":"427","DOI":"10.5414\/CNP70427","article-title":"Acute renal failure in a patient with severe malaria and dengue shock syndrome","volume":"70","author":"Thaha","year":"2008","journal-title":"Clinical Nephrology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1405","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/jphp.13067","article-title":"Baicalin reduces ciclosporin bioavailability by inducing intestinal p-glycoprotein in rats","volume":"71","author":"Tian","year":"2019","journal-title":"The Journal of Pharmacy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1410","author":"Tigecycline FDA Label"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1415","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s13318-011-0063-8","article-title":"Pharmacokinetics of micafungin in HIV positive patients with confirmed esophageal candidiasis","volume":"37","author":"Undre","year":"2012","journal-title":"European Journal of Drug Metabolism and Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1420","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa003","article-title":"Clinical efficacy of Ceftolozane-tazobactam versus other active agents for the treatment of bacteremia and nosocomial pneumonia due to drug resistant P. aeruginosa","author":"Vena","year":"2020","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1425","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/cid\/cir830","article-title":"Fidaxomicin: A novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection","volume":"54","author":"Venugopal","year":"2012","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1430","first-page":"119","article-title":"The disposition, metabolism and excretion of doripenem after a single intravenous dose of 500 mg in healthy male subjects","volume":"40","author":"Vermeir","year":"2008","journal-title":"Drug Metabolism Reviews"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1435","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/psc.1006","article-title":"Enfuvirtide effects on human erythrocytes and lymphocytes functional properties","volume":"14","author":"Vieira","year":"2008","journal-title":"Journal of Peptide Science"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1440","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12977-014-0088-6","article-title":"Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein","volume":"11","author":"Wan","year":"2014","journal-title":"Retrovirology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1445","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.fitote.2014.01.006","article-title":"Th17\/Treg imbalance in triptolide-induced liver injury","volume":"93","author":"Wang","year":"2014","journal-title":"Fitoterapia"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1450","doi-asserted-by":"crossref","first-page":"10111","DOI":"10.1038\/ncomms10111","article-title":"Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum","volume":"6","author":"Wang","year":"2015","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1455","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3389\/fcimb.2018.00418","article-title":"Baicalin weakens staphylococcus aureus pathogenicity by targeting sortase B","volume":"8","author":"Wang","year":"2018","journal-title":"Frontiers in Cellular and Infection Microbiology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1460","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMp1901233","article-title":"A temporizing solution to \u201cartemisinin resistance\u201d","volume":"380","author":"Wang","year":"2019","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1465","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1128\/AAC.00588-08","article-title":"Pharmacokinetics of high-dose oseltamivir in healthy volunteers","volume":"53","author":"Wattanagoon","year":"2009","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1470","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.2165\/00003495-200464150-00006","article-title":"Telithromycin","volume":"64","author":"Wellington","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1475","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijpharm.2017.12.037","article-title":"OAT1 and OAT3 also mediate the drug-drug interaction between piperacillin and tazobactam","volume":"537","author":"Wen","year":"2018","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1480","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/nrd1857","article-title":"Tigecycline","volume":"4","author":"Wenzel","year":"2005","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1485","article-title":"Safety and efficacy of fidaxomicin and vancomycin in children and adolescents with Clostridioides (Clostridium) difficile infection: A phase 3, multicenter, randomized, single-blind clinical trial (SUNSHINE)","author":"Wolf","year":"2019","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1490","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/jac\/dkn273","article-title":"Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects","volume":"62","author":"Wong","year":"2008","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1495","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1128\/AAC.36.2.318","article-title":"Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers","volume":"36","author":"Woodworth","year":"1992","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1500","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/147323000803600123","article-title":"Effect and mechanism of andrographolide on the recovery of Pseudomonas aeruginosa susceptibility to several antibiotics","volume":"36","author":"Wu","year":"2008","journal-title":"The Journal of International Medical Research"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1505","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.phymed.2018.04.063","article-title":"Baicalin protects mice against Salmonella typhimurium infection via the modulation of both bacterial virulence and host response","volume":"48","author":"Wu","year":"2018","journal-title":"Phytomedicine"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1510","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.biopha.2017.04.003","article-title":"Toxicity of triptolide and the molecular mechanisms involved","volume":"90","author":"Xi","year":"2017","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107671_bb1515","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4864","article-title":"Effect of CYP3A4 on liver injury induced by triptolide","volume":"34","author":"Xiao","year":"2020","journal-title":"Biomedical Chromatography"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1520","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24040742","article-title":"Inhibitory effects of berberine hydrochloride on trichophyton mentagrophytes and the underlying mechanisms","volume":"24","author":"Xiao","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1525","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejphar.2004.07.027","article-title":"Recent pharmacological studies on natural products in China","volume":"500","author":"Xing","year":"2004","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1530","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000445425","article-title":"Efficacy and safety of tigecycline for patients with hospital-acquired pneumonia","volume":"61","author":"Xu","year":"2016","journal-title":"Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1535","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/jcph.236","article-title":"Tigecycline pharmacokinetics, tolerability, safety, and effect on intestinal microflora in healthy Japanese male subjects","volume":"54","author":"Yamashita","year":"2014","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1540","first-page":"74","article-title":"Pharmacokinetics of the antifungal drug micafungin in mice, rats and dogs, and its in vitro protein binding and distribution to blood cells","volume":"50","author":"Yamato","year":"2002","journal-title":"Japanese Journal of Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1545","first-page":"206","article-title":"Study of binding of telithromycin to human serum proteins","volume":"51","author":"Yamazaki","year":"2003","journal-title":"Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1550","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1128\/AAC.00184-06","article-title":"Biochemical characterization of the interactions of the novel pleuromutilin derivative retapamulin with bacterial ribosomes","volume":"50","author":"Yan","year":"2006","journal-title":"Journal of Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1555","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2165\/00003495-200868060-00008","article-title":"Retapamulin: A review of its use in the management of impetigo and other uncomplicated superficial skin infections","volume":"68","author":"Yang","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1560","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2165\/0128071-200809060-00010","article-title":"Spotlight on retapamulin in impetigo and other uncomplicated superficial skin infections","volume":"9","author":"Yang","year":"2008","journal-title":"American Journal of Clinical Dermatology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1565","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.etp.2011.03.013","article-title":"Involvement of oxidative stress in the mechanism of triptolide-induced acute nephrotoxicity in rats","volume":"64","author":"Yang","year":"2012","journal-title":"Experimental and Toxicologic Pathology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1575","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/bdd.752","article-title":"Higher clearance of micafungin in neonates compared with adults: Role of age-dependent micafungin serum binding","volume":"32","author":"Yanni","year":"2011","journal-title":"Biopharmaceutics & Drug Disposition"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1580","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1002\/jps.22693","article-title":"Poor oral bioavailability of a promising anticancer agent andrographolide is due to extensive metabolism and efflux by P-glycoprotein","volume":"100","author":"Ye","year":"2011","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1585","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ijantimicag.2017.04.024","article-title":"In vivo development of tigecycline resistance in Klebsiella pneumoniae owing to deletion of the ramR ribosomal binding site","volume":"50","author":"Ye","year":"2017","journal-title":"International Journal of Antimicrobial Agents"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1590","author":"Zanamivir FDA Label"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1595","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1128\/AAC.00575-10","article-title":"Synergistic effect of 14-alpha-lipoyl andrographolide and various antibiotics on the formation of biofilms and production of exopolysaccharide and pyocyanin by Pseudomonas aeruginosa","volume":"55","author":"Zeng","year":"2011","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1600","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2165\/00003495-200969070-00003","article-title":"Ceftaroline: A novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus","volume":"69","author":"Zhanel","year":"2009","journal-title":"Drugs"},{"issue":"Suppl. 3","key":"10.1016\/j.pharmthera.2020.107671_bb1605","doi-asserted-by":"crossref","first-page":"S214","DOI":"10.1093\/cid\/cir920","article-title":"Oritavancin: Mechanism of action","volume":"54","author":"Zhanel","year":"2012","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1610","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3109\/00498254.2010.529180","article-title":"Intestinal absorption mechanisms of berberine, palmatine, jateorhizine, and coptisine: Involvement of P-glycoprotein","volume":"41","author":"Zhang","year":"2011","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107671_bb1615","first-page":"67","article-title":"Triptolide: Progress on research in pharmacodynamics and toxicology","volume":"155","author":"Zhang","year":"2014","journal-title":"Journal of Ethnopharmacology An Interdisciplinary Journal Devoted to Bioscientific Research on Indigenous Drugs"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1620","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.bbamem.2014.05.014","article-title":"Daptomycin forms cation- and size-selective pores in model membranes","volume":"1838","author":"Zhang","year":"2014","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1625","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/13880209.2018.1478431","article-title":"Influence of andrographolide on the pharmacokinetics of warfarin in rats","volume":"56","author":"Zhang","year":"2018","journal-title":"Pharmaceutical Biology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1630","doi-asserted-by":"crossref","first-page":"114024","DOI":"10.1016\/j.bcp.2020.114024","article-title":"Baicalein mediates protection against Staphylococcus aureus-induced pneumonia by inhibiting the coagulase activity of vWbp","volume":"178","author":"Zhang","year":"2020","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1635","doi-asserted-by":"crossref","first-page":"103899","DOI":"10.1016\/j.micpath.2019.103899","article-title":"Baicalin suppress growth and virulence-related factors of methicillin-resistant Staphylococcus aureus in vitro and vivo","volume":"139","author":"Zhang","year":"2020","journal-title":"Microbial Pathogenesis"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1640","first-page":"1","article-title":"The Drug metabolism and pharmacokinetics investigation about baicalin effect and baicalein on mice U14 cervical cancer","volume":"2015","author":"Zhanzhao","year":"2015","journal-title":"Journal of Spectroscopy"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1645","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1473-3099(14)71018-7","article-title":"Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: A randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial","volume":"15","author":"Zhong","year":"2015","journal-title":"The Lancet Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1650","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1248\/bpb.b13-00734","article-title":"Berberine inhibits fluphenazine-induced up-regulation of CDR1 in Candida albicans","volume":"37","author":"Zhu","year":"2014","journal-title":"Biological & Pharmaceutical Bulletin"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1655","doi-asserted-by":"crossref","first-page":"113962","DOI":"10.1016\/j.bcp.2020.113962","article-title":"Structure-activity relationship of flavonoid bifunctional inhibitors against Zika virus infection","volume":"177","author":"Zou","year":"2020","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1660","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.idc.2004.04.010","article-title":"Macrolides and ketolides: Azithromycin, clarithromycin, telithromycin","volume":"18","author":"Zuckerman","year":"2004","journal-title":"Infectious Disease Clinics of North America"},{"key":"10.1016\/j.pharmthera.2020.107671_bb1665","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.bbrc.2008.01.176","article-title":"Membrane curvature stress and antibacterial activity of lactoferricin derivatives","volume":"369","author":"Zweytick","year":"2008","journal-title":"Biochemical and Biophysical Research Communications"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820302011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820302011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:10:19Z","timestamp":1759011019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725820302011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":333,"alternative-id":["S0163725820302011"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107671","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and mechanism of actions of natural antimicrobial drugs","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107671","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107671"}}